This four part series, developed in partnership with Medical Minds, focuses on real-world practical approaches to the adoption of biosimilars and the data now available demonstrating the safety and efficacy of biosimilars in different clinical settings. Join us for part one of this series, taking place virtually on Feb. 24, at 8 p.m. EST. Our three panelists review the definition of a biosimilar; the development and approval process for biosimilars; and recent publications from the U.S. and Europe with an emphasis on clinical data in new starts with biosimilars versus originator biologics, switching between originator biologics and biosimilars in IBD, interchangeability, therapeutic drug monitoring, and immunogenicity.

 Register

Learning objectives

Upon completion of this series of discussion panels, learners will be able to:

• Describe biosimilar products and the lack of clinically meaningful differences between an FDA-approved biosimilar and the originator biologic.
• Implement practical approaches to incorporate biosimilars into clinical practice in the treatment of IBD.
• Gain increased confidence in discussing biosimilar options with their patients as part of shared decision making.
• Understand when switching from an originator to a biosimilar biologic is/is not appropriate.

Faculty

Christina Ha, MD, FACG, AGAF (Chair)
Associate Professor of Medicine
The F. Widjaja Foundation Inflammatory Bowel Immunology Research Institute
Cedars-Sinai

Raymond K. Cross, MD, MS, AGAF
Professor of Medicine Division of Gastroenterology and Hepatology
University of Maryland School of Medicine

Fernando Velayos, MD, MPH, AGAF
Professor of Medicine University of California San Francisco
Director, Regional Program in Inflammatory Bowel Disease
Northern California Kaiser Permanente

Pricing